GlassScriptPhysician profile
Yu-Ming Ni
NPI 1033565338
$8,250.81
in general payments reported to CMS, 2019-2025
38 companies · $1,671 in 2025
The $1,671 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $138 · 2021: $769 · 2022: $1,226 · 2023: $2,128 · 2024: $1,986 · 2025: $1,671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,785.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,006.12 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $781.09 | 2022-2025 | Jardiance |
| Abbott Laboratories | $700.48 | 2019-2025 | Cardiomems |
| Pfizer INC. | $676.09 | 2020-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $643.35 | 2021-2024 | Lifevest |
| Amgen INC. | $516.85 | 2021-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $330.28 | 2020-2025 | Farxiga, Lokelma, Wainua |
| Regeneron Healthcare Solutions, INC. | $328.99 | 2021-2025 | Evkeeza, Praluent |
| Abiomed | $308.95 | 2021-2024 | Impella |
| Novo Nordisk INC | $269.64 | 2024-2025 | Wegovy, Ozempic |
| Atricure, INC. | $263.17 | 2023-2025 | Atriclip Laa Exclusion System |
| E.R. Squibb & Sons, L.L.C. | $261.74 | 2020-2025 | Eliquis, Camzyos |
| Alnylam Pharmaceuticals INC. | $241.65 | 2023-2025 | Amvuttra, Onpattro |
| Shockwave Medical, INC | $222.94 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $171.66 | 2019-2024 | Lux-Dx Insertable Cardiac Monitor, Watchman Access System |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yu-Ming Ni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.